Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD
Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
This study is a pilot study designed to compare the safety and cardiovascular effects of 26
weeks of combination hydralazine/isorsorbide dinitrate therapy with placebo therapy in
patients receiving chronic hemodialysis.
The investigators hypothesize that treatment of chronic hemodialysis (ESRD) patients with a
combination of hydralazine/isosorbide dinitrate compared with placebo is safe and that it
will improve heart function as well blood flow/blood vessel supply.